Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) have earned a consensus rating of “Moderate Buy” from the thirteen brokerages that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, three have issued a hold rating, eight have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $86.3636.

Several research firms have issued reports on ARWR. Morgan Stanley upgraded Arrowhead Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $78.00 to $100.00 in a research note on Tuesday, April 21st. Wall Street Zen lowered Arrowhead Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. Leerink Partners increased their price objective on Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the stock a “market perform” rating in a research note on Wednesday. Royal Bank Of Canada increased their price objective on Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the stock an “outperform” rating in a research note on Friday, May 8th. Finally, HC Wainwright restated a “buy” rating and set a $100.00 target price on shares of Arrowhead Pharmaceuticals in a report on Wednesday, March 25th.

Arrowhead Pharmaceuticals Stock Performance

Arrowhead Pharmaceuticals stock opened at $81.82 on Friday. The company has a debt-to-equity ratio of 1.41, a current ratio of 6.23 and a quick ratio of 6.23. The stock has a fifty day moving average price of $74.25 and a two-hundred day moving average price of $67.68. Arrowhead Pharmaceuticals has a 52-week low of $14.30 and a 52-week high of $84.55. The firm has a market capitalization of $11.53 billion, a P/E ratio of -38.06 and a beta of 1.28.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.93) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.10) by $0.17. Arrowhead Pharmaceuticals had a negative return on equity of 55.09% and a negative net margin of 48.38%.The firm had revenue of $73.74 million during the quarter, compared to analyst estimates of $73.84 million. During the same period in the prior year, the company posted $2.75 earnings per share. The business’s revenue for the quarter was down 86.4% compared to the same quarter last year. As a group, analysts anticipate that Arrowhead Pharmaceuticals will post -3 EPS for the current fiscal year.

Insider Transactions at Arrowhead Pharmaceuticals

In other news, CFO Daniel Joseph Apel sold 13,095 shares of the stock in a transaction on Wednesday, April 22nd. The stock was sold at an average price of $71.35, for a total transaction of $934,328.25. Following the sale, the chief financial officer owned 162,905 shares in the company, valued at approximately $11,623,271.75. This represents a 7.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider James C. Hamilton sold 10,000 shares of the stock in a transaction on Thursday, April 23rd. The stock was sold at an average price of $75.00, for a total value of $750,000.00. Following the sale, the insider owned 226,958 shares in the company, valued at $17,021,850. The trade was a 4.22% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 26,065 shares of company stock worth $1,912,662. Insiders own 3.60% of the company’s stock.

Institutional Trading of Arrowhead Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. Tsfg LLC bought a new stake in shares of Arrowhead Pharmaceuticals during the fourth quarter valued at approximately $25,000. Optiver Holding B.V. grew its stake in shares of Arrowhead Pharmaceuticals by 83.8% during the first quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 186 shares during the last quarter. iSAM Funds UK Ltd bought a new stake in shares of Arrowhead Pharmaceuticals during the third quarter valued at approximately $29,000. First Horizon Corp bought a new stake in shares of Arrowhead Pharmaceuticals during the fourth quarter valued at approximately $32,000. Finally, WPG Advisers LLC grew its stake in shares of Arrowhead Pharmaceuticals by 384.8% during the fourth quarter. WPG Advisers LLC now owns 543 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 431 shares during the last quarter. 62.61% of the stock is owned by institutional investors.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.